News | January 29, 2022
DCGI approves Bharat Biotech’s Phase 3 trials for intranasal vaccine
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
UCB plans to submit regulatory applications in Q3 2022
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
It has also been granted permission to conduct trials for booster dose
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
_256_384.jpg)
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
Subscribe To Our Newsletter & Stay Updated
